AI Engines For more Details: Perplexity Kagi Labs You
Treatment of Psychotic Disorders: Atypical antipsychotics are used to manage symptoms of schizophrenia, bipolar disorder, and other psychotic disorders. They help alleviate symptoms such as hallucinations, delusions, disorganized thinking, and agitation.
Neurological Effects: These medications exert their effects by antagonizing dopamine receptors in the brain, particularly the D2 receptors. By blocking dopamine activity, they can help regulate neurotransmitter imbalances associated with psychotic symptoms.
Side Effects: Atypical antipsychotics may cause various side effects, including weight gain, metabolic changes (such as increased blood sugar levels and lipid abnormalities), sedation, extrapyramidal symptoms (such as tremors, rigidity, and akathisia), and hormonal disturbances (such as hyperprolactinemia).
Cardiac Effects: Some atypical antipsychotics, including remoxipride hydrochloride, have been associated with cardiac adverse effects, such as QT interval prolongation, which can increase the risk of arrhythmias and sudden cardiac death. This was one of the primary reasons for the withdrawal of remoxipride from the market in several countries.
Withdrawal from the Market: The decision to withdraw remoxipride hydrochloride from the market in various countries underscores significant safety concerns associated with its use. Healthcare providers and patients should be aware of these safety issues and consider alternative treatment options for psychotic disorders.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Akkermansiaceae | family | Decreases |
| 1 | 0 | Akkermansia | genus | Decreases |
| 0 | 1 | Ruminococcus | genus | Decreases |
| 0 | 1 | Fusobacterium | genus | Decreases |
| 0 | 1 | Mediterraneibacter | genus | Decreases |
| 0 | 1 | Lacticaseibacillus | genus | Decreases |
| 0 | 1 | Thomasclavelia | genus | Decreases |
| 0 | 1 | Lachnospira | genus | Decreases |
| 0 | 1 | environmental samples | no rank | Decreases |
| 0 | 1 | unclassified Akkermansia | no rank | Decreases |
| 1 | 0 | Akkermansia muciniphila | species | Decreases |
| 1 | 0 | Ruminococcus bromii | species | Decreases |
| 1 | 0 | Fusobacterium nucleatum | species | Decreases |
| 1 | 0 | [Ruminococcus] torques | species | Decreases |
| 1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
| 1 | 0 | Thomasclavelia ramosa | species | Decreases |
| 0 | 1 | Akkermansia glycaniphila | species | Decreases |
| 0 | 1 | Akkermansia massiliensis | species | Decreases |
| 0 | 1 | Candidatus Akkermansia intestinavium | species | Decreases |
| 1 | 0 | Lachnospira eligens | species | Decreases |
| 0 | 1 | Fusobacterium nucleatum subsp. nucleatum | subspecies | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 0.3 | 0.3 | |
| Allergic Rhinitis (Hay Fever) | 0.3 | -0.3 | |
| Allergies | 0.6 | 1.5 | -1.5 |
| Allergy to milk products | 0.7 | 0.7 | |
| Alzheimer's disease | 1.3 | 0.5 | 1.6 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.9 | 0.7 | 0.29 |
| Ankylosing spondylitis | 0.3 | 0.3 | 0 |
| Anorexia Nervosa | 0.2 | 0.2 | 0 |
| Asthma | 0.1 | 0.8 | -7 |
| Atherosclerosis | 0.3 | 0.3 | 0 |
| Atrial fibrillation | 0.2 | 0.2 | |
| Autism | 1.3 | 1.2 | 0.08 |
| Barrett esophagus cancer | 0.1 | 0.1 | |
| Biofilm | 0.2 | 0.2 | |
| Bipolar Disorder | 0.2 | 0.2 | 0 |
| Brain Trauma | 0.2 | -0.2 | |
| Breast Cancer | 0.2 | 0.2 | |
| Cancer (General) | 0.1 | 0.2 | -1 |
| Carcinoma | 0.5 | 0.2 | 1.5 |
| Celiac Disease | 0.5 | -0.5 | |
| Cerebral Palsy | 0.3 | 0.2 | 0.5 |
| Chronic Fatigue Syndrome | 0.8 | 0.2 | 3 |
| Chronic Kidney Disease | 0.2 | 0.5 | -1.5 |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.1 | 0.1 | 0 |
| Chronic Urticaria (Hives) | 0.5 | -0.5 | |
| Coagulation / Micro clot triggering bacteria | 0.2 | -0.2 | |
| Cognitive Function | 0.2 | 0.2 | |
| Colorectal Cancer | 1.1 | 1.1 | |
| Constipation | 0.2 | 0.2 | |
| Coronary artery disease | 0.2 | 0.2 | |
| COVID-19 | 1 | 1.5 | -0.5 |
| Crohn's Disease | 0.8 | 1.2 | -0.5 |
| deep vein thrombosis | 0.5 | 0.2 | 1.5 |
| Denture Wearers Oral Shifts | 0.2 | 0.2 | |
| Depression | 1 | 1.3 | -0.3 |
| Eczema | 0.1 | 0.1 | |
| Endometriosis | 0.2 | -0.2 | |
| Eosinophilic Esophagitis | 0.1 | 0.1 | |
| Epilepsy | 0.4 | 0.8 | -1 |
| erectile dysfunction | 0.1 | 0.1 | |
| Fibromyalgia | 0.1 | 0.1 | |
| Functional constipation / chronic idiopathic constipation | 0.2 | 0.4 | -1 |
| gallstone disease (gsd) | 0.2 | 0.4 | -1 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | 0 | 0 |
| Generalized anxiety disorder | 0.4 | 0.3 | 0.33 |
| Gout | 0.5 | 0.3 | 0.67 |
| Graves' disease | 0.2 | 0.2 | 0 |
| Gulf War Syndrome | 0.8 | -0.8 | |
| Halitosis | 0.3 | 0.3 | |
| Hashimoto's thyroiditis | 0.8 | 0.5 | 0.6 |
| Heart Failure | 0.5 | 0.5 | 0 |
| hemorrhagic stroke | 0.1 | 0.1 | |
| Hidradenitis Suppurativa | 0.1 | 0.1 | |
| High Histamine/low DAO | 0.2 | -0.2 | |
| hypercholesterolemia (High Cholesterol) | 0.5 | -0.5 | |
| hyperglycemia | 0.1 | 0.8 | -7 |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
| hypertension (High Blood Pressure | 1.3 | 0.5 | 1.6 |
| Hypothyroidism | 0.3 | 0.3 | |
| Hypoxia | 0.3 | 0.3 | |
| IgA nephropathy (IgAN) | 0.3 | 0.1 | 2 |
| Inflammatory Bowel Disease | 0.7 | 1.5 | -1.14 |
| Insomnia | 1 | -1 | |
| Intracranial aneurysms | 0.3 | 0.3 | |
| Irritable Bowel Syndrome | 1.5 | 1 | 0.5 |
| ischemic stroke | 0.2 | 0.2 | |
| Liver Cirrhosis | 0.6 | 1.2 | -1 |
| Long COVID | 0.5 | 1 | -1 |
| Low bone mineral density | 0 | 0 | |
| Lung Cancer | 0.7 | -0.7 | |
| Mast Cell Issues / mastitis | 0.2 | 0.2 | 0 |
| Menopause | 0.3 | -0.3 | |
| Metabolic Syndrome | 0.6 | 1.1 | -0.83 |
| Mood Disorders | 1.4 | 1.2 | 0.17 |
| multiple chemical sensitivity [MCS] | 0.3 | 0.3 | |
| Multiple Sclerosis | 1.1 | 0.2 | 4.5 |
| Multiple system atrophy (MSA) | 0.8 | 0.2 | 3 |
| neuropathic pain | 0.3 | -0.3 | |
| Neuropathy (all types) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.4 | 1 | -1.5 |
| NonCeliac Gluten Sensitivity | 0.5 | 0.5 | |
| Obesity | 1.5 | 1.7 | -0.13 |
| obsessive-compulsive disorder | 0.4 | 0.8 | -1 |
| Osteoarthritis | 0.1 | 0.5 | -4 |
| Osteoporosis | 0.2 | 0.5 | -1.5 |
| pancreatic cancer | 0.2 | 0.2 | |
| Parkinson's Disease | 1.6 | 0.4 | 3 |
| Polycystic ovary syndrome | 0.7 | 0.8 | -0.14 |
| primary biliary cholangitis | 0.1 | -0.1 | |
| Primary sclerosing cholangitis | 0.1 | 0.2 | -1 |
| Psoriasis | 0.5 | 0.5 | 0 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.1 | 0.1 | 10 |
| Rosacea | 0.4 | 0.4 | |
| Schizophrenia | 0.9 | 0.5 | 0.8 |
| scoliosis | 0.2 | -0.2 | |
| Sleep Apnea | 0.3 | 0.3 | |
| Slow gastric motility / Gastroparesis | 0.2 | 0.2 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.1 | 0.1 | |
| Stress / posttraumatic stress disorder | 0.4 | 0.5 | -0.25 |
| Systemic Lupus Erythematosus | 0.1 | 0.2 | -1 |
| Tic Disorder | 0.2 | 0.2 | |
| Tourette syndrome | 0.3 | 0.3 | |
| Type 1 Diabetes | 0.7 | 0.2 | 2.5 |
| Type 2 Diabetes | 0.6 | 1.2 | -1 |
| Ulcerative colitis | 0.5 | 1 | -1 |
| Unhealthy Ageing | 0.6 | 0.3 | 1 |
| Vitiligo | 0.2 | 0.3 | -0.5 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
